Can early TNF blockers stop arthritis drugs for good?
NCT ID NCT04435288
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether starting a strong TNF inhibitor (golimumab) early in peripheral spondyloarthritis can help patients reach drug-free remission, compared to the usual step-up approach with milder drugs. 90 adults with recent-onset disease will be randomly assigned to one of two strategies. The goal is to see if early, temporary treatment can reset the immune system and allow patients to stop all medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
golimumab (a TNF inhibitor)
What this could lead to
If successful, this could show that early, temporary use of a TNF inhibitor can lead to drug-free remission in some patients with peripheral spondyloarthritis.
What could go wrong
This is a relatively small phase 3 trial (90 participants) and remission may not be sustained long-term. The treatment also carries risks like increased infection and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL SPONDYLOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASZ Aalst
Aalst, 9300, Belgium
-
AZ Maria Middelares
Ghent, 9000, Belgium
-
AZ Sint-Jan
Bruges, 8000, Belgium
-
UZ Ghent
Ghent, 9000, Belgium
-
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
-
ZNA Jan Palfijn
Merksem, 2170, Belgium